MedTrace Logo

IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites

NCT01240486 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 207

Last updated 2014-05-19

No results posted yet for this study

Summary

Your child is able to participate in this study, if your child's doctor is planning to start your child on HAART (which is a combination of at least 3 anti HIV drugs). When your child is treated with HAART, the way your child's body is able to fight infection may change. The immune system is the body's defense against infection. Your child's immune system may respond in a stronger way to some types of infections that your child may already have. This immune response may cause your child to become sick and the condition is then called "immune reconstitution inflammatory syndrome" or IRIS.

Conditions

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    collaborator NIH

  • International Maternal Pediatric Adolescent AIDS Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Mark Cotton, MD · IMPAACT/Stellenbosch University

Eligibility

Min Age
4 Weeks
Max Age
72 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2013-02-28
Completion
2013-10-31

Countries

  • India
  • South Africa
  • Tanzania
  • Uganda
  • Zimbabwe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240486 on ClinicalTrials.gov